Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.

Abstract

Wilms tumor gene (WT1) mRNA expression in peripheral blood cells was examined in 80 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) transformed from MDS. Serum anti-WT1 antibody titers were also determined in 45 patients. Their long-term follow-up showed that the survival rate became worse as the WT1 mRNA level increased. In particular, a high WT1 mRNA level was a strong predictor of a short time to AML transformation even if adjusted by the International Prognostic Scoring System category. Moreover, high values of anti-WT1 antibody were an independent predictor of longer survival. These data may justify therapeutic strategies targeting WT1 molecules in MDS.

• Authors: Hideto Tamura, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Asaka Kondo, Hideya Hyodo, Kyoko Nakamura, Taishi Yamashita, Olga A Elisseeva, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama, Kiyoyuki Ogata
• Journal: Leukemia research (Leuk Res) Vol. 34 Issue 8 Pg. 986-90 (Aug 2010) ISSN: 1873-5835 [Electronic] England
• PMID: 20031209 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Chemical References

• Autoantibodies
• Biomarkers, Tumor
• WT1 Proteins

Topics

• Adult
• Aged
• Aged, 80 and over
• Anemia, Refractory (blood, genetics, immunology)
• Autoantibodies (blood)
• Biomarkers, Tumor (blood, genetics)
• Female
• Gene Expression Regulation, Leukemic
• Humans
• Leukemia, Myeloid, Acute (blood, genetics, immunology)
• Male
• Middle Aged
• Myelodysplastic Syndromes (blood, genetics, immunology)
• Prognosis
• Tumor Cells, Cultured
• WT1 Proteins (genetics, immunology)